Stanley Crooke compensation by year
IONIS PHARMACEUTICALS Summary Compensation Table · all 5 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
| Salary | $824,535 | $849,271 | $883,242 | $911,506 | $683,630 |
| Bonus | $1,205,882 | $1,006,068 | $759,257 | $925,748 | $587,665 |
| Stock awards | $1,427,416 | $1,306,509 | $1,870,630 | $3,712,677 | $3,908,663 |
| Option awards | $5,705,552 | $4,113,250 | $4,073,394 | $3,911,301 | $4,267,239 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $25,366 | $39,554 | $39,056 | $137,598 | $39,332 |
| Total | $9,188,751 | $7,314,652 | $7,625,579 | $9,598,830 | $9,486,529 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: IONIS PHARMACEUTICALS INC DEF 14A filed April 23, 2021, accession 0001140361-21-013999, and prior-year filings. Open the filing on EDGAR.
How this page was built: the IONIS PHARMACEUTICALS INC filed document, accession 0001140361-21-013999. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2021.
Equity holdings
unvested awards at FY2020 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 62,982 | $3,561,002 | — |
| RSU | 47,794 | $2,702,273 | — |
| RSU | 17,574 | $993,634 | — |
| RSU | 6,792 | $384,020 | — |
| Option | 3,397 | — | $47.34 |
| Option | 42,839 | — | $49.25 |
| Option | 74,688 | — | $53.77 |
| Option | 141,709 | — | $60.89 |
Per the Outstanding Equity Awards at Fiscal Year-End table in IONIS PHARMACEUTICALS INC's FY2020 proxy; value at the fiscal year-end close, as the company printed it.
IONIS PHARMACEUTICALS’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Brett Monia | President, Chief Executive Officer | $10,963,040 |
| Stanley Crooke · this page | Executive Chairman | $9,486,529 |
| Elizabeth Hougen | Executive Vice President, Finance and Chief Financial Officer | $4,341,100 |
| Richard Geary | Executive Vice President, Chief Development Officer | $4,011,036 |
| Patrick O’Neil | Executive Vice President, Legal, General Counsel and Corporate Secretary | $3,965,065 |
| Onaiza Cadoret-Manier | Executive Vice President, Chief Global Product Strategy and Operations Officer | $3,504,442 |
Board service
IONIS PHARMACEUTICALS board · FY2021| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2021 | $683,630 | $326,806 | $313,853 | $272,569 | $1,596,858 |
Each year as the company reported it in IONIS PHARMACEUTICALS's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: IONIS PHARMACEUTICALS pays directors a $60,000 cash retainer and $450,000 in Options and RSUs. As stated in IONIS PHARMACEUTICALS's FY2025 proxy.
The full IONIS PHARMACEUTICALS compensation record
free company briefThis page is one person within IONIS PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the IONIS PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are IONIS PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.